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Abstract: In the field of cancer therapy, lipid nanocapsules based on a core-shell structure 
are promising vehicles for the delivery of hydrophobic drugs such as docetaxel. The main 
aim of this work was to evaluate whether docetaxel-loaded lipid nanocapsules improved 
the anti-tumor effect of free docetaxel in breast cancer cells. Three docetaxel-loaded lipid 
nanocapsules were synthesized by solvent displacement method. Cytotoxic assays were 
evaluated in breast carcinoma (MCF-7) cells treated by the sulforhodamine B colorimetric 
method. Cell cycle was studied by flow cytometry and Annexin V-FITC, and apoptosis 
was evaluated by using propidium iodide assays. The anti-proliferative effect of docetaxel 
appeared much earlier when the drug was encapsulated in lipid nanoparticles than when it 
was free. Docetaxel-loaded lipid nanocapsules significantly enhanced the decrease in IC50 
rate, and the treated cells evidenced apoptosis and a premature progression of the cell cycle 
from G(1) to G(2)-M phase. The chemotherapeutic effect of free docetaxel on breast cancer 
cells  is  improved  by  its  encapsulation  in  lipid  nanocapsules.  This  approach  has  the 
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potential to overcome some major limitations of conventional chemotherapy and may be a 
promising strategy for future applications in breast cancer therapy. 
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1. Introduction 
Breast cancer is the most common malignant tumor and the first cause of morbidity and mortality 
among women worldwide [1,2]. The past century witnessed the maturation of chemotherapy as a viable 
adjuvant therapeutic modality for the treatment of cancer. Furthermore, in the case of breast disease, 
there have been advances in its early detection as well as in surgery, radiotherapy, and hormone therapy. 
The majority of women (>75%) with breast cancer are diagnosed at an early stage or are operable [3], 
and these patients require adjuvant chemotherapy to reduce the risk of recurrence [4,5]. 
Taxanes  (paclitaxel  or  docetaxel)  are  active  cytotoxic  agents  that  promote  the  polymerization  of 
tubulin and the stabilization of microtubules by preventing their disassembly. Adjuvant chemotherapy 
with taxanes reduces the risk of cancer recurrence and death in patients with early or operable breast 
cancer and has shown benefits in patients with high-risk node-negative breast cancer. However, although 
these novel chemotherapeutics have led to improvements in survival, they are associated with numerous 
drug-related toxicities [6]. Thus, docetaxel has been associated with a significant increase in neutropenia, 
febrile neutropenia, leucopenia, stomatitis, edema, fatigue and/or asthenia, and diarrhea [6]. These effects 
are due in part to the high doses used to achieve the desired anti-tumor effect, which are necessary 
because of the non-specific distribution of both novel and traditional chemotherapies, with only a small 
fraction of drugs reaching the tumor. It is well known that injected materials suffer from sequestration by 
the reticuloendothelial system, which is composed of monocytes and macrophages that clear foreign 
materials [7]. The drugs can accumulate in healthy organs, and there is a fine line between tolerability 
and severe morbidity, e.g., in the case of doxorubicin, a DNA intercalator that produces cardiotoxicity [8]. 
Moreover, the commercial formulation of docetaxel, Taxotere
®, is formulated with a high concentration 
of Tween 80 (40 g/L), which has been found to have severe side effects, including hypersensitivity 
reactions, cumulative fluid retention, and nausea and which has shown incompatibility with commonly used 
polyvinyl chloride intravenous administration sets [9]. Taken together, these factors compromise the curative 
potential of anticancer drugs, and more effective methods for their delivery to tumors are required [10]. 
Therefore, novel therapeutic approaches and alternative formulations of docetaxel with no (or low 
concentration) of Tween 80 are urgently needed to improve the efficacy of treatment in breast cancer 
patients with a poor prognosis. In this context, liposomes and polymer-drug conjugates were developed 
in the 1960s and 1970s [11] in attempts to apply Paul Ehrlich’s “magic bullet” concept to chemotherapy [12]. 
These  are  now  mainstay  platforms  in  nanomedicine,  a  multidisciplinary  field  that  aims  to  utilize 
nanoscale (1–100 nm) constructs to improve the delivery of chemotherapeutics [13]. Primarily, these 
carriers assist in drug solubilization and protect the drug from degradation. Their nanoscale size range 
and the frequently ubiquitous presence of poly (ethylene glycol) (PEG) or Pluronic
® F68 on their surface 
aids evasion of the reticuloendothelial system, allowing drugs to accumulate in tumors through enhanced 
permeability and retention, the result of tumor blood vessel leakiness [14,15]. Lower sequestration rates Int. J. Mol. Sci. 2012, 13  4908 
 
 
in healthy organs coupled with higher accumulation and retention rates in tumors would improve the 
effectiveness of treatments and minimize adverse effects. 
Lipid  nanocapsules  based  on  a  core-shell  structure  are  promising  vehicles  for  the  delivery  of 
hydrophobic drugs such as docetaxel. This study is the second part of a broader investigation of lipid 
nanocapsules. The first part was focused on the physicochemical characterization of three different lipid 
nanosystems [16]. The main aim of the present study was to evaluate whether docetaxel-loaded lipid 
nanocapsules improve the anti-tumor effect of free docetaxel in MCF-7 breast cancer cells. Indeed, we 
found a greater reduction in IC50 rate when the docetaxel was encapsulated in lipid nanoparticles, with 
evidence of apoptosis and premature cell cycle progression from G(1) to G(2)-M phase. 
2. Results and Discussion 
In cancer therapy, most proposed formulations present certain drawbacks related to low drug loading, 
toxicity,  and/or  an  unsuitable  release  pattern  [17].  Furthermore,  as  previously  noted,  docetaxel  is 
formulated  using  Tween  80  (polysorbate  80)  and  ethanol  (50:50,  v/v),  and  acute  hypersensitivity 
reactions have been noted in the majority of patients treated in phase I clinical trials, [18–20]. Fluid 
retention and hypersensitivity, among other reactions, are also associated with some other drugs with 
Tween 80 in their formulation [17]; therefore, this excipient may be partially responsible for some of the 
toxic  effects  observed  with  docetaxel  [21,22].  An  ideal  formulation  should  provide  biocompatible 
nanosized particles and high drug loading with sustained-release characteristics, allowing drug release in 
the target site at a therapeutic concentration, thereby minimizing drug inefficiency and adverse effects. 
Various approaches have been investigated in this line [21,23,24]. 
In the present study, we reformulated docetaxel in a better-tolerated and less-toxic vehicle to avoid 
premedication with corticosteroids and antihistamines, which is usually prescribed to reduce adverse 
reactions  associated  with  docetaxel  in  Tween  80.  Three  previously  obtained  and  characterized 
nanocapsule systems (16) were used to encapsulate docetaxel. All of them have a hydrophobic core 
constituted by olive oil, but they differ in their shell components. The shell of the simplest system (Epi), 
with an average diameter of 170 ±  20 nm, comprised a mixture of phospholipid molecules (Epikuron) 
and a poloxamer (Pluronic
® F68), which both act as colloidal stabilizers. Pluronic
® F68 possesses the 
capacity to avoid opsonin adsorption, thereby preventing the triggering of a cascade of immune system 
reactions that would eliminate the nanocapsules from the bloodstream [15]. Furthermore, because this 
poloxamer is not toxic, it can be used in nanoemulsions for the release of drugs and genes [25]. A second 
system (CS), with an average diameter of 330 ±  30 nm, was formulated by replacing the poloxamer with 
chitosan oligomers. Chitosan is a polysaccharide obtained from the deacetylation of chitin, which is a 
structural element of the exoskeleton of crustaceans. It is hydrophilic, biocompatible, and biodegradable 
and has low toxicity, and its effectiveness as an adsorption-enhancing agent has been demonstrated by 
various authors [26]. Finally, a third formulation (PhS), with an average diameter of 210 ±  20 nm, was 
designed to create a nanosystem in which Epikuron was replaced with phosphatidyl-serine, producing a 
carboxyl-functionalized nanosystem that offers the possibility of the efficient attachment of antibody 
molecules  for  future  vectorization  purposes  [16].  The  surface  electrical  state  of  the  different 
nanocapsules was analyzed by measuring their electrophoretic mobility as a function of the pH in low 
ionic strength media. Electrophoretic mobility is an experimental parameter directly related with the zeta Int. J. Mol. Sci. 2012, 13  4909 
 
 
potential and the surface potential, which is dependent of the surface composition and the salinity and pH 
of  the  medium.  The  zeta  potential  values  at  neutral  pH  agree  with  the  nature  of  the  shell  of  the 
nanocapsules, showing a positive surface charge (16.3 mV) for CS nanosystem, and a negative surface 
charge for Epi and PhS nanosystems (−56.4 mV and −44.4 mV respectively). 
2.1. Uptake Analysis 
Fluorescence microscopy studies were conducted to test the intensity of uptake by MCF-7 cells of the 
encapsulated Nile red. The uptake was significantly faster for Nile Red-CS nanocapsules than for the 
other two types. After only 1 h, CS particles showed the highest uptake, followed by Epi and then PhS 
particles (Figure 1). Uptake increased with longer incubation time, preserving these differences among 
particles until 5 h, when the cells showed the same amount of fluorescence, and no differences among 
the three types of nanoparticles could be detected. At 3 h of incubation, the Nile red was localized in the 
cytoplasm of cells (Figure 1), indicating that these nanosystems are effective vehicles to transport the 
molecules within MCF-7 cells by endocytosis, and can avoid efflux by cell membrane MDR transport 
proteins such as p-glycoprotein (P-gp) [25,27,28]. The variation in internalization among the different 
nanoparticles may be attributable to a combination of surface charge and hydrophilicity, which play a 
major  role  in  affinity  in  the  endocytosis  pathway  [29].  The  CS  nanocapsules  showed  the  highest 
fluorescence intensity, related to their positive superficial charge, which increases the affinity between 
nanoparticle and negatively-charged cell membrane [30]. This finding is consistent with the enhanced 
mucoadhesive properties reported for chitosan nanosystems [31,32]. The lower fluorescence response 
observed with the EPI and PhS systems appears attributable to the size and negative surface charge of 
these nanocapsules, as well as to the hydrophilic nature of the poloxamer molecules, which produce 
systems that  are more biocompatible but have a lower  cell uptake [33,34]. The lower fluorescence 
intensity of PhS versus EPI nanocapsules may be attributable to the lesser hydrophilicity of the former. 
Nevertheless, given that these differences disappear after 5 h of treatment, all three systems achieve 
similar uptake efficacy (data not shown). 
Figure 1. MCF-7 cells treated with: Nile Red- EPI nanocapsules for (a) 1 h and (b) 3 h; Nile 
Red-CS nanocapsules for (c) 1 h and (d) 3 h (f); or Nile Red-Phs nanocapsules for (e) 1 h 
and (f) 3 h; (g) Localization of Nile Red in the cytoplasm; the cell nucleus is stained with 
DAPI; (h) Blank: cells treated with empty nanocapsules. (a, c, e, f and g: × 40 magnification; 
b, d: × 20 magnification). 
 Int. J. Mol. Sci. 2012, 13  4910 
 
 
2.2. Synthesis, Encapsulation Efficiency, and Cytotoxicity Assays of Docetaxel-Loaded Nanoparticles  
Docetaxel-loaded  nanoparticles  were  prepared  by  using  a  solvent-displacement  technique.  For 
encapsulation, docetaxel was dissolved in olive oil from the organic phase of the emulsion before it was 
mixed  with  the  aqueous  phase.  High-performance  liquid  chromatography  (HPLC)  study  of  the 
encapsulation efficiency of docetaxel showed that the organic phase of CS, Epi, and PhS nanoparticles 
contained 86%, 80%, and 80% of the drug, respectively. In cytotoxicity assays, MCF-7 cells were treated 
with  free  docetaxel  or  increasing  concentrations  of  the  different  docetaxel-loaded  nanocapsules  for  
6 days, followed by calculation of the inhibitory concentration 50 (IC50) in each case. No significant 
differences in growth patterns were found between parental MCF-7 cells and MCF-7 cells treated with 
empty CS, Epi, or PhS nanoparticles (data not shown). With equivalent drug loading in the culture 
medium,  a  markedly  lower  proliferation  rate  was  observed  in  the  MCF-7  cells  treated  with  
docetaxel-loaded nanoparticles than in the parental MCF-7 cells treated with free docetaxel (Figure 2).  
A 20 nM dose of free docetaxel had no cytotoxic effect on cells, whereas 20 nM of docetaxel-loaded CS, 
Epi, or PhS nanoparticles induced a significant decrease of 94.65%, 89.27%, or 51.01%, respectively, in 
their  survival  rate  (P  <  0.001)  (Figure  2a).  IC50  values  were  45  nM  for  free  docetaxel,  9  nM  for 
docetaxel-loaded CS and Epi nanoparticles, and 20 nM for docetaxel-loaded PhS nanoparticles (Figure 2b). 
Figure  2. (a) Growth-inhibition curves of MCF-7 cells after 6 days of exposure to free 
docetaxel and to the three docetaxel-loaded nanoparticles (Epi, CS and PhS). Values are the 
mean of four independent experiments; (b) IC50 values (drug concentration producing 50% 
reduction in absorbance in control cells) of free docetaxel and the three docetaxel-loaded 
nanoparticles,  expressed  in  nM  and  estimated  as  described  in  Material  and  Methods.  
* Statistically significant. 
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Figure 2. Cont. 
 
Recent studies reported similar effects with high-dose docetaxel in oily core nanocapsules. Youm et al. [35] 
observed that the bioactivity against SUM 225 cells was higher for free versus encapsulated docetaxel 
at lower concentrations (2.5 μM), but was significantly higher for the encapsulated form at the highest 
concentration (5 μM).  Likewise,  Li  et  al. [36] found that  cell death  was  greater in  drug-resistant  
MCF-7/ADR  cells  when  doxorubicin  was  delivered  in  LA-TPGS  nanoparticles  at  high  drug 
concentrations. Importantly, the Epi, CS, and PhS nanocapsules described in the present study induced 
high cell death levels even at low concentrations, exerting a five-fold (Epi and CS) and 2.26-fold (PhS) 
more potent cytotoxic effect versus free docetaxel. These data indicate that the sustained release of the 
drug and its enhanced drug internalization by MCF-7 cells when in this nanocapsule formulation may 
increase the biological response to docetaxel and allow a decrease in the dose, thereby reducing its  
side effects. 
2.3. Apoptosis Determinations and Cell Cycle Analysis 
Apoptosis is considered the main cell death mechanism in response to taxanes. Docetaxel targets 
tubulin, stabilizing microtubules and thereby inducing cell-cycle arrest and apoptosis [37]. We therefore 
studied these well-documented effects on cell cycle distribution and apoptosis in the tumor cells. When 
undergoing apoptosis, cells externalize phosphatidylserine, a lipid found on the inner surface of the cell 
membrane  that  can  be  labeled  with  fluorochrome-conjugated  annexin  V.  It  is  therefore  possible  to 
distinguish between intact cells (stained negative for both annexin V-FITC and propidium iodide [PI]), 
early apoptosis (stained positive for annexin V-FITC and negative for PI), late apoptosis or cell death 
(stained positive for both annexin V-FITC and PI), and necrosis (stained positive for PI). 
Our flow cytometry study with annexin V assay showed that 94.30% of control MCF-7 culture cells 
were viable, 1.05% were early apoptotic, 0.35% were in late or final stages of apoptosis, and 4.30% 
were necrotic (P < 0.001) (Figure 3). No significant differences versus control cells were found in 
MCF-7 cells treated for 24 h with empty nanoparticles (data not shown). No apoptosis was detected in 
cells treated with 45.2 nM free docetaxel for 24 h. Significant apoptosis levels were observed in cells 
treated with docetaxel-loaded nanoparticles, and the highest apoptosis level (16.19%) was in the cells 
treated with 9.1 nM of Epi docetaxel-loaded nanoparticles (Figure 3a–e). The confocal microscopy Int. J. Mol. Sci. 2012, 13  4912 
 
 
study  confirmed  these  results  (Figure  3f–j).  In  fact,  it  is  known  to  be  difficult  to  demonstrate 
programmed cell death by known apoptosis-inducing agents in the MCF-7 human breast cancer cell 
line, and only a few cytotoxic agents have been found to act preferentially via an apoptotic mechanism 
in human breast cancer cells [38,39]. 
Figure  3.  Quantification  of  docetaxel-induced  apoptosis  in  MCF-7  cells  by  
fluorescence-activated cell sorting analysis (a, b, c, d and e) and confocal laser scanning 
microscopy (f, g, h, i, and j). Cells were incubated with free docetaxel or docetaxel-loaded 
Epi. CS, or PhS nanoparticles for 24 h. Untreated cells served as controls. Cells were stained 
with annexin V and PI to evaluate apoptotic cell death (see Materials and Methods): (a and f) 
MCF-7 control cells, (b and g) free docetaxel, (c and h) docetaxel-loaded Epi, (d and i) 
docetaxel-loaded CS, (e and j) docetaxel-loaded PhS. On confocal laser scanning, early 
apoptosis (stained positive for annexin V-FITC and negative for PI), late apoptosis or cell 
death (stained positive for both annexin V-FITC and PI) and necrosis (stained positive for 
PI) can be observed; viable cells are not visible (stained negative for both annexin V-FITC 
and PI). Data are representative of four separate experiments. 
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Figure 4. Representative flow cytometry profiles of the cell cycle phase distribution of 
MCF7 cells (a,b). Cells were incubated with free docetaxel or docetaxel-loaded Epi, CS, or 
PhS nanoparticles for 24 h. Untreated cells served as controls. Cells were subsequently 
fixed and stained with propidium iodide for DNA content analysis. Data are representative 
of four separate experiments. 
 
(a) 
Cell Cycle Phases  Control  Free Docetaxel  EPI-Docetaxel  CS-Docetaxel  PhS-Docetaxel 
G0/G1 (%)  85.21 ±  4.18  63.32 ±  1.04  62.15 ±  3.07  61.49 ±  2.5  60.87 ±  1.05 
G2/M (%)  11.12 ±  0.2  14.44 ±  0.18  19.57 ±  0.15  19.55 ±  0.09  20.23 ±  1.17 
S (%)  3.67 ±  0.01  22.24 ±  0.2  18.29 ±  1.0  18.97 ±  1.01  18.91 ±  1.19 
(b) 
It has also been reported that docetaxel acts at molecular level by impairing mitosis and inducing 
cell-cycle arrest [40]. We performed flow cytometry studies to determine differences in cell cycle Int. J. Mol. Sci. 2012, 13  4914 
 
 
distribution among the treatments. Figure 4 depicts the results of treating MCF-7 cells for 24 h with 
free or nanocapsule-loaded docetaxel at IC50 values. All treatments induced accumulation in G2/M and 
S  phases,  with  a  significant  decrease  in  G0/G1  phase  versus  control  cells.  The  accumulation  was 
significantly greater in cells treated with docetaxel-loaded nanoparticles than in cells treated with the 
free  drug  (Figure  4).  The  rapid  decrease  in  cell  cycle  progression,  evidenced  by  the  increased 
percentage of cells in S and G2/M phase, is in agreement with previous reports that docetaxel treatment 
induces a G2 cell cycle buildup in several cell lines, including MCF-7 [41–43]. 
3. Experimental Section 
3.1. Cell Lines and Culture Conditions 
The human breast cancer MCF-7 cell line was grown at 37 ° C in an atmosphere containing 5% CO2 
with Dulbecco’s modified Eagle Medium (DMEM) (Gibco, Grand Island, NY, USA) supplemented 
with  10%  (v/v)  heat-inactivated  fetal  bovine  serum  (FBS)  (Gibco)  2%  L-glutamine,  2.7%  sodium 
bicarbonate, 1% Hepes buffer, and 1% penicillin/streptomycin solution (GPS, Sigma). 
3.2. Lipid Nanocapsule Preparation 
Lipid  nanosystems  were  prepared  and  characterized  as  described  in  [16].  Three  systems  were 
formulated:  EPI  nanocapsules,  with  surface  shell  composed  of  Epikuron  and  Pluronic
®  F68;  CS 
nanocapsules,  with  shell  of  Epikuron  and  chitosan  oligomers;  and  PhS  nanocapsules,  with  shell  of 
phosphatidyl-L-serine  and  Pluronic
®  F68.  For  nanosystem  characterization,  the  average  size  was 
determined by combining a high-performance-particle-sizer technology with a non-invasive-backscattering 
method, in which the measurement is taken at an angle of 173° . A Zetasizer-Nano analyzer (Malvern 
Instruments, Worcestershire, UK) was used to measure the electrophoretic mobility (µ e). Zeta potential 
was calculated from this experimental magnitude in physiological medium conditions. 
Fluorescent lipid nanocapsules were formulated by dissolving Nile Red in the olive oil phase at a 
concentration of 0.025% (w/w). Encapsulation of this fluorescent molecule was confirmed by using a 
SPEX Fluoromax-2 spectrofluorometer. Emission fluorescence spectra were determined from 550 to 
700 nm at an excitation wavelength of 485 nm, with a scanning speed of 100 nm/min and wavelength 
accuracy of ± 1 nm. 
Docetaxel-loaded lipid nanocapsules were formulated by dissolving docetaxel in the olive oil phase 
at  a  concentration  of  0.1%  (m/w).  The  encapsulation  efficiency  was  calculated  by  HPLC  at  the 
Scientific  Instrumentation  Center  of  the  University  of  Granada,  using  a  SHIMADZU  LC-20AC 
chromatograph with SPD-M20A diode array detector and C8 Nova-Pak Cartridge column (4 microns, 
4.6 × 150 mm); detection was performed at a wavelength of 230 nm. 
3.3. Uptake Studies 
MCF-7 cells (5 ×  10
3) were seeded into 6-well plates under the culture conditions detailed above. After 
24 h, cells were fed with fresh medium and treated with Nile Red nanocapsules. Cells were incubated with 
Nile Red labeled particles for 1 h and 5 h and then washed twice with acidic phosphate saline buffer (PBS) Int. J. Mol. Sci. 2012, 13  4915 
 
 
to  remove  free  nanocapsules.  Fresh  PBS  was  added  and  living  cells  were  analyzed  by  fluorescent 
microscopy (Nikon Eclipse Ti-S). Cells treated with empty nanoparticles were used as controls. 
3.4. Cytotoxicity Assays in Vitro 
MCF-7 cells (1 ×  10
3) were plated into 6-well plates under the culture conditions detailed above. 
The cells were fed with fresh medium and increased concentrations of free and encapsulated drug 
every alternate day up to the end of the experiment. After 6 days of treatment, cells were counted using 
sulforodamine-B (SRB) colorimetric assay as previously described [44] using a Titertek Multiscan 
apparatus (Flow, Irvine, CA, USA) at 492 nm. 
We evaluated the linearity of the SRB assay with cell number using stock MCF-7 cells before each 
cell growth experiment. IC50 values were calculated from semi-logarithmic dose-response curves by 
linear interpolation. All experiments were plated in triplicate wells and were carried out at least twice. 
3.5. Apoptosis Detection by Staining with Annexin V-FITC and Propidium Iodide 
The Annexin V-FITC Apoptosis Detection kit I (Pharmingen, San Diego, CA, USA) was used to 
detect apoptosis by flow cytometry. MCF-7 cells (1 ×  10
6 cells) were plated onto 75-cm
2 flasks and 
cultured overnight, followed by incubation with IC50 values of free or encapsulated docetaxel for 24 h. 
Cells were harvested by PBS-EDTA, washed twice in cold PBS (1.4 M NaCl, 27 mM KCl, 100 mM 
KH2PO4/K2HPO4,  pH  7.2),  and  pelleted  by  centrifugation  at  500  g  for  10  min.  They  were  then 
resuspended at 10
6 cells/100 µL in a binding buffer (Hepes buffer, 10 mM, pH 7.4, 150 mM NaCl,  
5 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2), stained with annexin V incubation reagent (1 µL annexin  
V-FITC (25 µg/mL), 10 µL binding buffer, 10 µL PI (50 µg/mL), and 79 µL H2O) and incubated in 
the  dark  for  15  min  at  room  temperature.  Then,  500  µL  binding  buffer  was  added  and  the  cells  
(10,000  cells  per  sample)  were  immediately  analyzed  using  a  FACScan  flow  cytometer  (Becton 
Dickinson, San Jose, CA, USA). All experiments were performed in triplicate and yielded similar results. 
3.6. Cell Cycle Distribution Analysis 
Cells at 70% of confluence were treated with the half maximal inhibitory concentration (IC50) of 
free or encapsulated docetaxel. Cells in monolayer culture were harvested, washed twice with sample 
buffer (100 mg glucose; 100 mL PBS without Ca
2+ or Mg
2+), and fixed in 70% (v/v) cold ethanol for 
up to 1 week. Cells were pelleted, washed once with sample buffer, and resuspended in PI solution  
(50 µg/mL PI, 0.5 mg/mL RNase in sample buffer, pH 7.4) for 30 min in the dark. Fluorescence 
activated cell sorting (FACS) analysis was performed after 24 h of treatment. All experiments were 
performed in triplicate and yielded similar results. 
4. Conclusions 
In  conclusion,  our  three  lipid  core-shell  nanocapsules  appear  to  be  excellent  platforms  for  the 
encapsulation  and  delivery  of  docetaxel  into  human  cancer  cells,  especially  in  cancers  that  are  
drug-resistant through efflux pump activity. Our carriers, especially the CS and Epi nanoparticles, 
favor a fast and efficient uptake of the encapsulated drug into tumor cells. Moreover, the encapsulated Int. J. Mol. Sci. 2012, 13  4916 
 
 
docetaxel maintained its full activity and preserved its mechanism of action, characterized by apoptosis 
and premature cell cycle progression from G(1) to G(2)-M phase. Our results suggest that the use of 
lipid nanocapsules may allow doses of docetaxel to be decreased without loss of therapeutic effect, 
thereby reducing the drug toxicity. It also avoids any adverse effect of excipients (e.g., Tween 80), and 
may constitute a promising strategy for future applications in breast cancer therapy. 
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